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Abstract
Introduction: As antiretroviral treatment (ART) continues to expand in resource-limited countries, the emergence of HIV drug
resistance mutations (DRMs) is challenging in these settings. In Gabon (central Africa), no study has yet reported the virological
effectiveness of initial ART given through routine HIV care.
Methods: Following the World Health Organization (WHO) recommendations, a cross-sectional study with a one-time HIV-1 RNA
viral load (VL) measurement was conducted in Gabon to assess virological failure (VF) defined by a VL result ]1000 copies/ml
and DRMs among adult patients living with non-B HIV-1 strains and receiving first-line non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based antiretroviral therapy for at least 12 months. Risk factors associated with VF and DRMs were assessed.
Results: Between March 2010 and March 2011, a total of 375 patients were consecutively enrolled from two decentralized (one
semirural and one rural) HIV care centres. Median time on ART was 33.6 months (range, 12107). Overall, the rate of VF was
41.3% (36.446.4). Among viremic patients, 56.7% (80/141) had at least one DRM and 37.6% had dual-class resistance to
nucleoside reverse transcriptase inhibitors (NRTIs) and NNRTIs. The most frequent DRMs were K103N/S (46.1%) and M184V/I
(37.6%). Thymidine analogue mutations were found in 10.6%. Independent risk factors associated with VF were being followed
up at the semirural centre (P0.033), having experienced unstructured treatment interruptions (P0.0044), and having low
CD4
 counts at enrolment (PB0.0001). A longer time on ART (P0.0008) and being followed up at the rural centre (P0.021)
were risk factors for DRMs.
Conclusions: This is the first study conducted in Gabon providing VF rates and DRM patterns in adult patients receiving first-line
ART. In sub-Saharan Africa, where NNRTI-based regimens are recommended as the standard for first-line ART, strengthening
virological monitoring together with preventing unplanned treatment interruptions are a global public health priority.
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Introduction
Over the past decade, the roll-out of antiretroviral therapy
(ART) has dramatically increased in low- and middle-income
countries. More than six million people were receiving ART in
these countries at the end of 2010 [1,2]. As ARTcontinues to
expand in resource-limited settings, the emergence of HIV
drug resistance mutations (DRMs) is challenging. Due to the
absence of virological monitoring in routine clinical care
together with the use of antiretroviral (ARV) drugs with low
genetic barriers (such as 3TC and non-nucleoside reverse
transcriptase inhibitors [NNRTIs]), concerns remain regarding
the emergence of high-level resistance during first-line
therapy. If ART regimens are not effectively delivered,
DRMs could become widespread, leading to an increase in
therapeutic failures, transmission of drug-resistant viruses,
and a decrease in therapeutic options, treatment program
effectiveness, and survival. Thus, as recommended by the
World Health Organization (WHO), besides determining rates
of transmitted DRMs, monitoring acquired DRMs emerging
during treatment is crucial in resource-limited countries [3,4].
In Gabon (a country of 1.4 million inhabitants located in
central Africa) where HIV-1 seroprevalence is high (approxi-
mately 6%) [5], ART became available in 2001 through the
gradual implementation of ARV centres. To date, there is a
network of 10 centres located throughout the nine provinces
of the country [6]. Of the approximately 53,000 Gabonese
subjects living with HIV-1, 10,000 were receiving ART by the
end of 2009. Currently, ART is initiated when CD4 counts
are 5350 cells/ml, according to the WHO 2010 guidelines
[7]. Due to financial and technical constraints, biological
monitoring is restricted to CD4 counts, and remains asso-
ciated with limited, if any, plasma HIV-1 RNA viral load (VL)
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1measurements [8]. In Gabon, no study has yet reported the
effectiveness of initial ART given through routine HIV care.
Here we assessed virological failure (VF) rates and HIV DRMs
among approximately 400 patients receiving ART for at least
12 months in two (semirural or rural) ARV centres in Gabon.
Materials and Methods
Study design and settings
According to the WHO recommendations [4], we conducted a
cross-sectional study by performing a one-time HIV-1 RNA VL
measurement free of cost to patients meeting the following
criteria: (i) being confirmed HIV-1-positive; (ii) ]18 years
old; (iii) being on first-line ART for at least 12 months; and
(iv) and consenting to participate in the study. The study was
approved by the ethical biomedical research committee of
Franceville (No. 023/2010/MESRS/CERB). After information
about the study, an oral informed consent was obtained from
all patients. All data were anonymized for further analysis.
Patients were consecutively enrolled from two HIV care
centres. One ARV centre, located at Franceville (a city of
70,000 inhabitants), was a semirural site managing a total
of approximately 1000 patients on ART. The second centre,
located at Koulamoutou (a small town of 15,000 inhabitants)
was a rural setting with approximately 400 treated subjects.
A standardized form was filled out by medical doctors to
record the following variables: sex, age, ARV use (date, name,
switch), and previous CD4 counts obtained at ART initiation.
Previous history of unstructured treatment interruptions
(TIs) was also extracted from clinical records. Treatment
interrupters were defined as subjects who defaulted and
returned to care during their follow-up. When available, the
duration of unplanned TIs was recorded. Patients who were
transferred to other care centres were not considered as
interrupters. If patients had a treatment interruption at the
time of blood sampling, they were excluded from this survey.
Laboratory testing
Whole blood specimens were collected in EDTA tubes at
each centre. For Franceville, they were processed within six
hours at the Centre International de Recherches Me ´dicales
de Franceville (CIRMF) Retrovirology Laboratory. After cen-
trifugation, plasma was frozen at 808C. For Koulamoutou,
plasma specimens were processed similarly in the centre,
stored at 208C, and transported by road in a cool box once
per week to the CIRMF Retrovirology Laboratory.
HIV seropositivity was confirmed using an in-house
serotyping V3 immunoassay [9]. CD4 counts at enrolment
were determined with flow cytometry (Fascount, Becton
Dickinson, San Jose, CA). Plasma HIV-1 RNA levels were deter-
mined using the HIV Generic Viral Load assay (Biocentric,
Bandol, France) [10]. This HIV-1 RNA test has a sensitivity
threshold of 300 copies/ml by using 200 ml of plasma.
Genotypic DR tests were carried out among viremic patients
with VF (defined as a HIV-1 RNA viral load result ]1000
copies/ml, according to the WHO 2010 recommendations)
[11], using a previously described in-house assay [12]. ARV
drug resistance mutations (DRMs) were identified and in-
terpreted using the Agence Nationale de Recherches
sur le SIDA (ANRS) algorithm (May 2011) (http://www.
hivfrenchresistance.org). Mutations were also studied using
the Stanford HIVdb genotypic resistance algorithm and then
coded as major resistant mutations using the International
AIDs Society (IAS) list from January 2012 (http://hivdb.
stanford.edu). HIV-1 subtyping was performed by phyloge-
netic analysis of pol region sequences. Our laboratory
participated in the 2011 quality control assessment of
HIV-1 drug resistance sequencing implemented by the
ANRS [13].
Statistical analysis
All statistical analyses were performed using Stata 10
TM
software (Houston, TX). First, a comparison of patients’
characteristics between the two care centres was made using
the x
2 for categorical variables and the Mann-Whitney-U test
for continuous variables. Second, VF (]1000 copies/mL) and
DRM prevalence rates with 95% confidence intervals (95%
CIs) were determined. Third, logistic regression models were
used to examine the following explanatory variables as
potential factors associated with VF: gender, age, centre,
time on ART, unstructured TIs, and CD4 count at ART initiation
(month 0) and at the time of VL assessment.The same seven
variables plus HIV-1 RNA levels were further examined as
predictors of at least one significant DRM among patients
with VF. Finally, all variables with P-values B0.2 in univariate
analyses were entered in multivariate analyses.
Results
From March 2010 to March 2011, a total of 375 adult patients
on first-line ARTwereconsecutively included (Table 1). In both
sites, more women were enrolled and most patients were
thus women (74%). The median age of women was slightly
lower than for men (40.8 years versus 47.7 years). Except one
woman who tested positive to subtype O strain, all subjects
harboured HIV-1 variants belonging to group M. A large
majority (357/375, 95.2%) of patients were receiving two
nucleoside reverse transcriptase inhibitors (NRTIs) plus
one NNRTI (combination of D4T/AZT/ABC3TCNVP/EFV)
whereas approximately 4% (n14, including 11 women)
started a protease inhibitor (PI)-based regimen. Four (ap-
proximately 1%) additional patients (including three women)
were receiving TDF3TCEFV.The switch mainly concerned
replacement of D4T by AZT or NVP by EFV. At ART initiation
(M0), the overall median CD4
 count was 159 cells/ml (IQR,
70248), with no significant difference between women (158
cells/ml) and men (164 cells/ml). At the time of enrolment, the
median time on treatment was 33.6 months (range, 12107)
and was slightly higher for males (35.4 months) compared
with females (32.3 months).The median CD4
 count reached
337 cells/ml (IQR, 215492), with very similar values for
women (334 cells/ml) and men (343 cells/ml). Previous
unstructured TIs were recorded in more than 40% of patients
(in women and men), with an overall median duration of
seven months. There was no significant difference in the
patients’ characteristics between the two care centres except
the median time on ARV therapy, which was slightly longer in
the semirural site than in the rural centre (P0.03). Also
unstructured TIs were more frequently recorded in patients
Lie ´geois F et al. Journal of the International AIDS Society 2012, 15:17985
http://www.jiasociety.org/index.php/jias/article/view/17985 | http://dx.doi.org/10.7448/IAS.15.2.17985
2from the semirural centre (approximately 46%) versus the
rural site (approximately 33%) (P0.05).
Overall, 171 (45.6%; 95% CI, 40.650.7) had a VL ]300
copies/ml and were therefore defined as viremic on ART,
with a median of 49,900 copies/ml (IQR, 5805388,000).
When using a threshold value of 400 copies/ml, 165 (44.0%;
95% CI, 39.049.1) subjects were viremic. For drug resistance
assessment, genotypic tests were only done among the 155
(41.3%) viremic patients with a VL result ]1000 copies/ml.
Overall, 141/155 (91.0%) virus were successfully sequenced
(ten could not be amplified and four had insufficient volume)
and showed a very high HIV-1 genetic diversity. Although the
predominant HIV-1 variants were CRF02_AG (n46/141,
32.6%) and subtype A (n23, 16.3%), 15 additional sub-
types/CRFs (including subtypes G [n11], D [n7],
C[ n 3], H [n3], F2 [n1], J [n1] and CRF37_cpx
[n9], CRF01_AE [n5], CRF25_cpx [n5], CRF11_cpx
[n3], CRF06_cpx [n1], CRF09_cpx [n1], CRF36_cpx
[n1], CRF43_02G [n1], and CRF45_cpx [n1]) and
19 mosaic unique recombinant forms (URFs) were also
identified.
By using the ANRS algorithm, among the 141 sequenced
specimens, 80 (56.7%) harboured ]1 DRM (Figure 1).
Overall, 53 (37.6%) showed dual-class resistance to NRTIs
and NNRTIs, 24 (17.0%) harboured resistance to NNRTIs only,
and three (2.1%) were only resistant to NRTIs. Around two-
thirds of viral strains from patients with DRMs were resistant
to at least two or three of the drugs constituting their ARV
regimens. No clinically relevant protease resistance mutation
was found amongst the four viremic patients with first-line
PI-based regimens. Identical results were obtained using the
Stanford HIVdb algorithm.
Of the 56 NRTI-associated DRMs, M184V/I selected by
3TC/FTC was the most frequent (n53, 37.6%), followed by
any thymidine analogue resistance TAM mutation (n15,
10.6%). Ten patients had viruses with the TAM-1 mutation
Table 1. Baseline characteristics of 375 HIV-1-positive patients treated with first-line ARV regimens in Gabon
Variables Women (n277) Men (n98) Total (n375
a)
Age
Median, years (IQR) 40.8 (34.546.9) 47.7 (41.553.2) 42.2 (35.848.9)
HIV V3 serotyping, n (%)
HIV-1 M 266 (96.0) 93 (94.9) 359 (95.7)
HIV-1 O 1 (0.4) 0 1 (0.3)
HIV-1 N 0 0 0
HIV-1 P 0 0 0
HIV-2 0 0 0
Negative
b 10 (3.6) 5 (5.1) 15 (4.0)
First-line ARV regimen, n (%)
D4T/AZT/ABC3TCNVP/EFV
c 263 (94.9) 94 (95.9) 357 (95.2)
2 NRTIs (D4T/AZT/DDI/3TC/ABC)1P I
d 11 (4.0) 3 (3.1) 14 (3.7)
TDF3TCEFV 3 (1.1) 1 (1.0) 4 (1.1)
Time on ART (months)
1223 84 (30.3) 27 (27.6) 111 (29.6)
2435 71 (25.6) 20 (20.4) 91 (24.3)
]36 122 (44.1) 51 (52.0) 173 (46.1)
Median (IQR) 32.3 (20.649.7) 35.4 (21.350.9) 33.6 (21.250.4)
Unstructured treatment interruptions
n (%) 122 (44.0) 40 (40.8) 162 (43.2)
Duration
e, median (IQR) (months) 6 (213) 10 (621) 7 (315)
Recurrent events (n) 43/119 (36.1) 13/43 (30.2) 56/162 (34.6)
CD4
 count at ART initiation
Median, cells/ml (IQR) 158 (76249) 164 (65247) 159 (70248)
CD4
 count at enrolment
Median, cells/ml (IQR) 334 (217501) 343 (202484) 337 (215492)
aIncluding 300 patients from the semirural centre (Franceville) and 75 from the rural centre (Koulamoutou).
bThe 15 samples found negative with the V3 serotyping HIV ELISA were found positive by HIV-1 western blot (New Lav Blot I, Bio-Rad, Marnes-
La-Coquette, France).
cD4T(n121/)/AZT(n215)/ABC(n21)3TCNVP(n78)/EFV(n279).
dIDV, n6; NFV, n4; LPV/r, n4.
eThe duration of unstructured TIs was recorded for 101 patients.
Abbreviations: ART, antiretroviral therapy; D4T, stavudine; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; IDV, indinavir; ABC,
abacavir; DDI, didanosine; LPV/r, ritonavir-boosted lopinavir.
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3T215Y/F associated with AZT/D4T resistance. Other TAM-1
were M41L (n2) and L210W (n1). TAM-2 mutations
included K219Q/E/R (n4), D67N/G (n4), and K70R
(n3). Three (3.7%) patients had viruses with at least three
of these TAMs associated with AZT/D4T resistance. No
patient harboured viruses having accumulated TAMs that
confer also cross-resistance to ddI or ABC or TDF. No patient
displayed viruses harbouring the K65R or K70E mutation
selected by TDF. Two patients had HIV-1 strains harbouring
the multi-NRTI resistance Q151M mutation associated with
M184V/I and Y188L.
Among the 77 (54.6%) patients harbouring viruses
resistant to at least one molecule of the NNRTIs class, the
most commonly detected DRM was the K103N/S (n65,
46.1%). Major NNRTIs DRMs were also obtained at positions
P225H (n12), K101E (n11), Y181C (n10), G190A
(n7), Y188L (n6), V90I (n5), E138A/G (n5), M230L
(n4), A98G (n3), H221Y (n3), L100I (n3), V179D
(n2), and V106I (n1). In two patients treated with
NVP, viruses were found resistant to etravirine (ETV), the
second generation NNRTI drug, due to the simultaneous
presence of the Y181C and H221Y mutations. Five additional
viruses were predicted to be possibly resistant to ETV,
including three viruses harbouring the E138A/G/Q/R DRM,
one with the three DRMs K101E/H/I/P/R, Y181C, and G190A/
S, and one with the three DRMs V90I, K101E/H/I/P/R, and
G190A/S.
Independent factors associated with VF were being fol-
lowed up at the semirural site (P0.033), having experienced
unstructured treatment interruptions (P0.0044), and hav-
ing low CD4
 counts at enrolment (PB0.0001) (Table 2).
We found no significant association between VF and sex
(P0.24), age, or CD4 at M0. A longer time on ART (P
0.0008) and being followed up at the rural centre (P0.021)
Figure 1. Frequency (forest plots) of drug resistance mutations in 141 viremic HIV-1-positive patients from Gabon and treated with first-line
NNRTI-based antiretroviral therapy.
Squares represent estimates and bars 95% confidence intervals (CIs). Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside
reverse-transcriptase inhibitors.
M41L, L210W, and T215Y mutations are indicative of the TAM-1 pathway; D67N/G, K70R, T215F, and K219Q/E/R mutations are indicative of the TAM-2 pathway.
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4Table 2. Risk factors associated with VF and DRMs among HIV-1-positive patients treated with first-line ARV regimens in Gabon
VF DRM]1
Variables
VLB1000 cp/ml
(N220)
VL]1000 cp/ml
(N155) P
a P
b
No
(N61)
Yes
(N80) P
a P
b
Sex, n (%) 0.24  0.95 
Male 63 (63.6) 36 (36.4) 14 (43.8) 18 (56.2)
Female 157 (56.9) 119 (43.1) 47 (43.1) 62 (56.9)
Age (years), median (IQR) 42.1 (36.850.2) 42.3 (35.347.9) 0.17 0.3 42.4 (34.447.0) 41.6 (35.848.0) 0.22 
Time on ART (years), median (IQR) 32.9 (21.348.8) 33.1 (20.452.9) 0.4 24.1 (17.540.0) 42.4 (25.257.9) 0.012 0.00008
HIV care centre, n (%) 0.01 0.0033 0.083 0.021
Rural 54 (72.0) 21 (28.0) 5 (25.0) 15 (75.0)
Semirural 166 (55.3) 134 (44.7) 56 (46.3) 65 (53.7)
Unstructured treatment interruptions, n (%) B0.0001 0.044 0.14 0.34
No 149 (70.0) 64 (30.0) 28 (50.9) 27 (49.1)
Yes 71 (43.8) 91 (56.2) 33 (38.4) 53 (61.6)
CD4
 count at ART initiation, median, cells/ml
(IQR) 161 (69250) 157 (80240) 0.9  156 (94245) 122 (54237) 0.33 
CD4
 count at enrolment, median, cells/ml
(IQR) 412 (295566) 229 (120350) B0.0001 B0.0001 232 (139349) 213 (110309) 0.42 
HIV-1 RNA VL (log10 cp/ml), median (IQR)    5.14 (3.985.83) 4.98 (4.195.66) 0.74 
aUnivariate analysis;
bMultivariate analysis.
Abbreviations: VL, viral load; VF, virological failure; DRM, drug resistance mutation; ART, antiretroviral treatment; IQR, interquartile range.
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5were risk factors for DRMs. We found no significant associa-
tion between the presence of DRMs and sex (P0.95), age,
or CD4 at M0. VL levels were not associated with DRM
acquisition (Table 2).
Discussion
Here, for the first time in Gabon, we provided VF rates
and DRM patterns in adult patients living with non-B HIV-1
strains and receiving mostly ( 95%) first-line thymidine
analogue, 3TC, and NNRTI-based ART for a median period
of 34 months. Our survey, conducted in semirural and
rural settings, first revealed a high rate of VF, with 41% of
patients showing VL results ]1000 copies/ml. In our survey,
a history of unplanned treatment interruptions and CD4

counts at inclusion were strong predictors of VF. Also, a
higher VF rate was found for the semirural care centre.
Second, among participants who virologically failed ART,
56.7% carried ]1 DRM and almost 40% had dual-class
resistance to NRTIs and NNRTIs. DRMs were consistent with
expected patterns given first-line NNRTI-based therapy
predominantly used in Gabon. The proportion of patients
with DRMs significantly increased with time on ART and was
higher for the rural site.
Comparison of VF (or success) and DRM profiles rates
obtained in different African populations must be made
cautiously because study design, VL assays and threshold
used, and duration of ART at time of failure may vary. In a
review, Barth and colleagues reported virological success
(defined by a VL B400 cp/ml) rates in sub-Saharan Africa of
78%, 76%, and 67% after 6, 12, and 24 months of ART,
respectively [8]. Compared with those pooled data, the
success rates found herein by using an identical sensitivity
threshold (B400 cp/ml) were consistent for the rural centre
(68% for a median of 28 months of treatment) but potentially
lower for the semirural centre (53.0% for a median of 35
months of treatment).
In addition, the burden of DRMs found in our survey was
consistent with previous studies in which prevalence of
DRMs showed highly contrasted results, with NNRTI muta-
tions ranging from 47 to 100%, the M184V/I mutation from
24 to 81%, and any TAM from 0 to 63% [1422]. However, in
our study, it must be noted that patients from the semirural
site had infrequent DR mutations, albeit with a higher rate
of VF as mentioned here. One reason for explaining varying
patterns of VF and drug resistance may be related to
transient episodes of viremia due to patient-initiated un-
structured treatment interruptions that are a reality of
routine clinical care in African ART programs [23]. In our
survey, they were more frequent at the semirural site in
comparison with the rural centre. They implied patient-
related factors (such as incomplete adherence, difficulties
with payment for travelling to the HIV care centre and/or
for routine biological tests, and toxicity and side effects of
ART regimens), as well as program-related factors (such as
pharmacy stock-outs). The impact of structured treatment
interruptions (STIs) on virological outcomes has been pre-
viously reported through randomized STI trials [2426]. For
instance, in the Trivacan trial conducted in Ivory Coast,
Danel et al. obtained 24% of drug-resistant viruses in a two-
months-off, four-months-on ARTarm, compared with 9% in a
continuous strategy arm, with a highly significant difference
for resistance to mostly NNRTIs. By contrast, very few studies
‘‘in real world settings’’ investigated the impact of unplanned
treatment interruptions on the development of DRMs
[23,27]. In our setting, we think that early transient viremia
may occur prior to the accumulation of DRMs or may be
associated with a reversion to wild type viruses. As a con-
sequence, among patients having experienced unstructured
treatment interruptions, resistance would not be identified
as frequently.
Our study is limited by its cohort cross-sectional design
and does not provide any information on the overall
efficiency of the national ART program. Even if it is known
that rates of lost to follow-up are higher in the first year and
tend to decrease thereafter, no information was available on
the dropout/death rates of the clinics and on the presence
(or not) of DRM before ART initiation. In addition, subjects
with a VL result ranged between 300 and 1000 copies/ml
may harbour mutant HIV strains with DRMs. Therefore, the
drug resistance rate that we obtained in our study is most
likely a minimal estimate. Another limitation of our study is
represented by the fact that no data on baseline prevalence
of HIV drug resistance was available for our studied popula-
tion. However, all studies recently conducted among un-
treated Gabonese subjects revealed low levels (51%) of
transmitted HIV DR [5,28,29]. Finally, we were not able to
fully investigate gender-related differences in virological
outcomes given the relatively small sample size for men
and the lack of information for a history of ARV prophylaxis to
prevent mother-to-child transmission (MTCT) among women
enrolled in our study.
Conclusions
In summary, this is the first study conducted in Gabon
providing VF rates and DRM patterns in adult patients
receiving first-line ART. In sub-Saharan Africa, where NNRTI-
based regimens are recommended as the standard of care for
first-line ART, strengthening virological monitoring aimed at
early failure detection, together with preventing unintended
treatment interruptions, are a global public health priority.
Access to virological monitoring should be also increased
to limit the level and complexity of drug resistance observed
in non-B HIV-1 strains circulating in resource-limited settings.
Increase in VL monitoring will prevent inappropriate switches
and preserve susceptibility to second-line regimens in Africa
[3032]. As reported recently by Wallis and colleagues in
South Africa [33], it is feasible to obtain low (510%) rates of
VF and less complex drug resistance profiles using the
D4T3TCEFV/NVP regimens.
Finally, the WHO/HIVResNet Global HIV drug resistance
(HIVDR) prevention, surveillance, and monitoring strategy
must be strengthened worldwide at sentinel sites to inform
national health authorities on the efficiency of first-line ART
and to allow recommendations on future ART strategies. Our
study showed that, in the vast majority of our patients, the
second-line regimen recommended by WHO would be active
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6in our settings. Nevertheless, a minority showed complex
drug resistance profiles predictive of resistance to the usual
second-line regimens. Emerging multi-NRTI resistance in sub-
Saharan Africa would not only compromise second-line
treatment options and the success of antiretroviral roll-out
but could also contribute to the spread of drug-resistant
variants worldwide [34]. Thus frequent VL monitoring is
definitively required to limit the threat of increased trans-
mitted resistance in the face of continuing incident infection
as observed in Gabon.
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